Tiziana Life Sciences Ltd. has announced the initiation of patient enrollment in its Phase 2 randomized, placebo-controlled clinical trial investigating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in early Alzheimer's disease. The trial will evaluate foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab or donanemab. According to the company, the first patient is expected to be dosed next week. Baseline clinical assessments, cognitive testing, TSPO-PET imaging, and biomarker collection have been completed in initial participants. Results from the study have not yet been presented and will be available in the future.